Induced pluripotent stem cell (iPSC) technology holds great promise for advancing applied and basic biomedical research by bringing relevant human biology into the laboratory. Human cells that can recapitulate native behavior and are amenable to large-scale scientific manipulation, offer a new and highly relevant model for phenotypic screening and target identification; endpoints that are a primary goal of both pharmaceutical and academic endeavors.
During their presentations, the panelists will cover recent and ongoing accomplishments utilizing human iPS cell-derived cardiomyocytes. Case studies will be presented that describe the design and implementation of phenotypic screens for cardioprotective molecules and potential therapeutic avenues for cardiac hypertrophy as well as methods for validating key proteins, and thus potential therapeutic targets, in dilated cardiomyopathy. Together these specific examples highlight advances in the practical implementation of iPS cell-based technologies as a whole and point to how the promise of this technology is transforming biomedical research.
Anne Bang, Ph.D., director of cell biology at Conrad Prebys Center for Chemical Genomics within the Sanford Burnham Medical Research Institute, will discuss her findings from high-content screen analyses for small molecules that reverse induced hypertrophic phenotypes in iCell® Cardiomyocytes.
Siobhan Malany, Ph.D., chemical biology leader, also at Conrad Prebys Center for Chemical Genomics, will present her findings from high-throughput chemical biology screens for small molecule inhibitors that prevent or delay oxidative stress-induced death of cardiomyocytes during cell therapy.
Finally, Jason Thomas Maynes, M.D., Ph.D., director of research for anesthesia and pain medicine at the Sick Kids Research Institute within the Hospital for Sick Children, will describe his approach of using iPS cell-derived iCell Cardiomyocytes to model clinical disease, with a particular focus on how to identify new therapeutics.